PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchiTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
mRNA cancer vaccines are investigational treatments designed for people who already have cancer. They give cells temporary instructions for making selected tumor antigens, so immune cells—especially T cells—may learn to recognize and attack cancer cells carrying those targets. They are not routine preventive vaccines, and current evidence does not establish them as a cure or as an approved standard treatment.
What are mRNA cancer vaccines?
They are a type of therapeutic cancer immunotherapy. Rather than preventing an infection before it happens, a cancer treatment vaccine aims to direct a patient’s immune response against antigens associated with an existing tumor. An antigen is a molecule or fragment that the immune system can recognize.
Some candidates target tumor-associated antigens shared by a group of patients. Others are personalized: they are designed around mutations identified in an individual patient’s tumor. The purpose of either approach is to help immune cells distinguish cancer cells bearing the selected targets from other cells. That aim is not a guarantee that the immune system will recognize every tumor cell or that treatment will control the cancer.
The mRNA is an instruction molecule, not a piece of the tumor itself. In general, mRNA is translated in the cell’s cytoplasm, is short-lived, and does not enter the nucleus or alter DNA. Those properties explain how the platform is intended to work; they do not establish whether a particular vaccine is effective.
Popular on Amazon
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
For a general overview of cancer treatment vaccines and their distinction from preventive vaccines, see the National Cancer Institute’s cancer treatment vaccines guide.
How do mRNA cancer vaccines work?
The basic idea is to deliver instructions for selected tumor antigens, then use the body’s antigen-presentation and T-cell systems to build a targeted response. The steps below describe the intended process for a personalized neoantigen vaccine; designs and clinical protocols can differ.
- Analyze a tumor sample. Genetic sequencing looks for mutations in the tumor that may produce tumor-specific neoantigens. A neoantigen is a new or altered antigen associated with tumor mutations.
- Choose candidate targets. Computational algorithms and immunologic criteria help identify mutations whose resulting antigens might be presented to, and recognized by, the patient’s T cells. Prediction is not certainty: a predicted target may not be processed or displayed effectively, or T cells may fail to recognize it.
- Encode the selected antigens. The chosen sequences are included in an mRNA construct. The mRNA may be packaged in lipid nanoparticles, which are intended to protect it and help deliver it into cells.
- Make the antigen proteins. Antigen-presenting cells, including dendritic cells, take up the mRNA and translate its instructions into antigen proteins.
- Display antigen fragments. The cells break the proteins into fragments and display them using major histocompatibility complex (MHC) molecules. This is one way immune cells are shown what to look for.
- Prime T cells. T cells that recognize matching displayed antigens may be activated. The intended response includes cytotoxic T cells, which can attack target-bearing cells, and memory T cells, which may support longer-lasting recognition.
Dendritic cells are often described as immune-system teachers because they present antigens to T cells. The National Cancer Institute quotes Karine Breckpot, Ph.D., of Vrije Universiteit Brussel, explaining that they educate T cells so they can search for and kill cancer cells or virus-infected cells. This is a simplified description: successful treatment also depends on whether the selected targets are present and accessible and whether the tumor environment permits immune cells to act.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What is the difference between personalized and shared-antigen vaccines?
Personalized vaccines are tailored to mutations found in one patient’s tumor; shared-antigen vaccines are designed around targets found in a subset of patients. The choice affects how targets are selected and whether each vaccine must be individually designed.
Personalized neoantigen vaccines
A personalized design starts with a tumor sample and selects mutations believed likely to generate recognizable neoantigens. Multiple selected targets can be encoded in one construct. Tailoring may help focus the immune response on features of that tumor, but “personalized” means the design is individualized—not that efficacy is assured. Tumors can contain different cell populations, and not every cancer cell necessarily carries every selected mutation.
Also popular on Amazon
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
Shared-antigen vaccines
A shared design focuses on a mutation or protein that occurs across a subset of patients. KRAS-related targets are one example of an active research area. A shared target may not require the same individualized target-selection process, but it is relevant only when the patient’s cancer has the target the vaccine is designed to address. The available data does not establish a broadly applicable shared-antigen product as routine care.
Combination treatment
Some studies pair a vaccine with an immune-checkpoint inhibitor or another treatment. The rationale is that a vaccine may prime or expand T cells, while a combination treatment may help address barriers to their activity inside a tumor. The contribution of each treatment cannot be inferred from a combination result alone; study design and comparison groups matter.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →What is V940, also called mRNA-4157?
V940, or mRNA-4157, is an investigational individualized therapeutic vaccine. The National Cancer Institute’s Drug Dictionary describes it as encoding 20 patient-specific neoantigen epitopes, with the intent of stimulating cytotoxic and memory T-cell responses. An epitope is the part of an antigen recognized by an immune response.
A September 10, 2026 review in Nature Communications, “Developing neoantigen cancer vaccines: where are we now?”, summarizes early and randomized melanoma research involving V940 with pembrolizumab, an immune-checkpoint inhibitor. In the reported phase 2b comparison, the review describes a 44% reduction in disease recurrence at a median 24-month follow-up and a 49% reduction in risk of recurrence and/or death at a three-year median follow-up. These are results from a particular melanoma study and combination, not a vaccine-alone effect, a cure rate, or an estimate that can be applied to other cancers. The review describes phase 3 trial NCT05933577 as ongoing; phase 3 confirmation is important to determining whether earlier results hold up.
The same review reports that in a cited phase 1 study of mRNA-4157 plus pembrolizumab, 60% of patients developed de novo CD8+ T-cell responses and 40% developed de novo CD4+ T-cell responses. These are immune-response measurements, not evidence that the same share of patients were cured or lived longer. Immune activity and patient-centered outcomes such as recurrence, progression, or survival answer different questions.
Also popular on Amazon
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
SW1115C3 is another personalized mRNA cancer-vaccine concept listed by the NCI. Its described design sequences the tumor, encodes selected neoantigens in a single mRNA molecule, and relies on antigen-presenting cells to display the resulting antigens through MHC molecules. Being listed as a concept does not mean it is approved or available as standard treatment.
Are mRNA cancer vaccines approved, and can patients get one now?
The sources summarized here describe mRNA cancer vaccines as investigational, with leading candidates in clinical development rather than routine treatment. The NCI’s general overview says no mRNA cancer vaccine had FDA approval when that page was published; the 2026 review describes phase 3 confirmation of a leading candidate as ongoing. This evidence does not establish that an mRNA cancer vaccine is currently FDA-approved.
Access, when available, is through a clinical trial rather than an assumption that a vaccine can be requested as ordinary care. Trial availability and eligibility depend on the specific study, cancer type and stage, prior or planned treatments, and other protocol criteria. A patient’s oncology team can explain whether a trial is relevant and where to verify its current status. A study result in one group does not establish that a different patient or cancer type will benefit.
mRNA cancer vaccines should also not be confused with non-mRNA cancer treatment vaccines. Sipuleucel-T is an FDA-approved non-mRNA cancer treatment vaccine, as the NCI distinguishes in its overview; its existence does not mean mRNA cancer vaccines have the same regulatory status.
What cancers are being studied?
The cited evidence includes melanoma and early-stage triple-negative breast cancer research, as well as active work on shared-antigen strategies such as KRAS-directed vaccines. The American Association for Cancer Research’s 2026 Cancer Progress Report describes durable neoantigen-specific T-cell responses in an individualized mRNA-vaccine study in early-stage triple-negative breast cancer. That is an immune-response finding; it should not be read as proof of a cure or as evidence that all patients with that cancer benefit.
Recommended Free Tools
Also popular on Amazon
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Widely Compatible: Transform any USB-C port into a USB-A port and USB-A port into a USB-C port, and connect up a wide range of USB-C(including MacBook, iPad Pro/Air/Mini, iPhone models with USB C ports, Samsung Galaxy series, and Google Pixel series. ) and USB A devices(including external hard drives, phones, mice, printers, and more)
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
These examples show why the phrase “mRNA cancer vaccines” covers a research field, not one treatment with one result. Studies differ in cancer type, stage, target selection, vaccine design, combination therapy, and outcome measured. Evidence in melanoma or an early-stage breast cancer study does not establish efficacy in another cancer, and immune responses do not automatically translate into fewer recurrences or longer survival.
Are mRNA cancer vaccines a cure?
No cure rate or universal efficacy percentage is established for mRNA cancer vaccines as a class. A recurrence reduction reported in one randomized melanoma comparison is encouraging evidence for that particular setting, but it does not prove that a vaccine cures cancer, works on its own, or benefits every cancer type.
Several scientific challenges help explain the gap between a promising immune response and a reliable clinical benefit:
- Target prediction is imperfect. A mutation selected by an algorithm may not produce an antigen that is processed, presented, or recognized by T cells.
- Tumors are heterogeneous and can evolve. A vaccine may target only some tumor-cell clones, while other cells lack the selected targets or change over time.
- The tumor microenvironment can suppress immune activity. T cells may be primed yet still have difficulty acting within the tumor.
- Manufacturing takes time for personalized products. The NCI’s 2022 explainer described roughly one to two months from biopsy and sequencing to vaccine preparation in the programs discussed. That timing is program-specific, not a universal turnaround guarantee.
- Important design questions remain open. Researchers continue to study which antigens to select, how to deliver them, when to vaccinate, and which treatment combinations are most useful.
For these reasons, trial phase and endpoint matter. Early immune-response measurements can show that a vaccine engages the immune system. A randomized comparison can assess clinical outcomes against a control group, while a confirmatory study tests whether a finding is sufficiently robust to support broader conclusions.
What side effects can they cause?
There is no single established safety profile for every mRNA cancer-vaccine candidate. The NCI’s general cancer-treatment-vaccine page lists possible flu-like symptoms, fever, chills, weakness, dizziness, nausea or vomiting, muscle or joint aches, fatigue, headache, breathing difficulty, and blood-pressure changes. Which effects occur and how serious they are can depend on the vaccine, dose, cancer, extent of disease, and the patient’s health.
Also popular on Amazon
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Those general possibilities should not be mistaken for a product-specific rate or a complete list for an individual trial. Safety information for a particular candidate and combination should come from the clinical-trial team and its consent materials. If someone enrolled in a study develops a new or concerning symptom, the study team or treating clinician is the right point of contact; breathing difficulty or other severe symptoms warrant urgent medical attention.
How should patients interpret claims about these vaccines?
Look for the exact cancer type, stage, vaccine, combination, study phase, follow-up period, and endpoint behind a claim. Those details determine what a result can—and cannot—say.
- “T-cell response” means an immune measurement; it is not synonymous with tumor shrinkage, recurrence prevention, or longer survival.
- “Reduced risk” refers to a comparison within a particular study. It is not the percentage of patients cured, and it does not specify an individual’s personal chance without further context.
- “Personalized” describes how the vaccine target is selected. It does not mean the vaccine is guaranteed to fit every tumor cell or to work.
- “In a trial” means the treatment is being studied under a protocol. It does not establish approval, routine availability, or suitability outside the study.
The most useful question for an oncologist is not simply whether a cancer vaccine exists, but whether a specific study matches the patient’s cancer and treatment situation, what endpoint it is testing, and what alternatives or standard treatments apply.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Frequently Asked Questions
Are mRNA cancer vaccines the same as COVID-19 mRNA vaccines?
They use the general idea of delivering mRNA instructions, but the intended target and clinical purpose differ. Cancer candidates aim to direct immunity toward tumor-associated or tumor-specific antigens in people who already have cancer; that shared platform does not make the products interchangeable.
Does mRNA from a cancer vaccine change a patient’s DNA?
The general biology described for mRNA is that it is translated in the cytoplasm, is short-lived, and does not enter the nucleus or alter DNA. This describes the molecule’s usual role, not proof of effectiveness for any specific vaccine candidate.
Why might a personalized cancer vaccine take weeks to prepare?
The process can require a tumor sample, sequencing, selection of candidate neoantigens, and construction of an individualized mRNA sequence. The NCI’s 2022 explainer described roughly one to two months for programs discussed at that time, but that is not a guaranteed schedule for every candidate or patient.
Can someone receive an mRNA cancer vaccine alongside chemotherapy or immunotherapy?
Some investigational approaches are studied in combination with other treatments, including immune-checkpoint inhibitors. Whether a combination is appropriate depends on the specific trial protocol and clinical situation; patients should not change or delay prescribed treatment based on general descriptions of vaccine research.
Free tools Windows power users keep installed
One-click scans. No signup required.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
